Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R

Carrie Haskell-Luevano, Siska Hendrata, Cheryl North, Tomi K. Sawyer, Mac E. Hadley, Victor J Hruby, Chris Dickinson, Ira Gantz

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

[Nle4,DPhe7]-α-MSH (NDP-MSH), a highly potent analogne of α- melanocyte-stimulating hormone (α-MSH), possesses nanomolar efficacies at all the melanocortin receptor subtypes except the MC2R. Evaluation of the melanocortin 'message' sequence of [Nle4,DPhe7]-α-MSH was performed on the human melanocortin receptor subtypes designated hMC1, hMC3R, hMC4R, and hMC5R. Tetrapeptides and tripeptides were stereochemically modified to explore topochemical preferences at these receptors and to identify lead peptides possessing agonist activity and subtype selectivity. Four peptides were discovered to only bind to the hMC1 and hMC4 receptor subtypes. The tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 (1) possessed 0.6μM binding affinity at the hMC1R, 1.2μM binding affinity at the hMC4R, and agonist activity at both receptors. The tripeptides Ac-DPhe-Arg-Trp-NH2 (6) and Ac-DPhe-Arg- DTrp-NH2 (7) possessed 2.0 and 9.1 μM binding affinities, respectively, only at the hMC4R, and both compounds effected agonist activity. The tetrapeptide Ac-His-Phe-Arg-DTrp-NH2 (4) possessed 6.3μM affinity and full agonist activity at the hMC1R, while only binding 7% at the hMC3R, 36% at the hMC4R, and 11% at the hMC5R at a maximal concentration of 10 μM. These data demonstrate that the His-Phe-Arg-Trp message sequence of the melanocortin peptides does not bind and stimulate each melanocortin receptor in a similar fashion, as previously hypothesized. Additionally, this study identified the simplest structural agonists for the hMC1R and hMC4R receptors reported to date.

Original languageEnglish (US)
Pages (from-to)2133-2139
Number of pages7
JournalJournal of Medicinal Chemistry
Volume40
Issue number14
DOIs
StatePublished - Jul 4 1997

Fingerprint

Melanocortin Receptors
Peptidomimetics
Melanocyte-Stimulating Hormones
Melanocortins
Peptides
argininamide

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Haskell-Luevano, C., Hendrata, S., North, C., Sawyer, T. K., Hadley, M. E., Hruby, V. J., ... Gantz, I. (1997). Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. Journal of Medicinal Chemistry, 40(14), 2133-2139. https://doi.org/10.1021/jm960840h

Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. / Haskell-Luevano, Carrie; Hendrata, Siska; North, Cheryl; Sawyer, Tomi K.; Hadley, Mac E.; Hruby, Victor J; Dickinson, Chris; Gantz, Ira.

In: Journal of Medicinal Chemistry, Vol. 40, No. 14, 04.07.1997, p. 2133-2139.

Research output: Contribution to journalArticle

Haskell-Luevano, C, Hendrata, S, North, C, Sawyer, TK, Hadley, ME, Hruby, VJ, Dickinson, C & Gantz, I 1997, 'Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R', Journal of Medicinal Chemistry, vol. 40, no. 14, pp. 2133-2139. https://doi.org/10.1021/jm960840h
Haskell-Luevano, Carrie ; Hendrata, Siska ; North, Cheryl ; Sawyer, Tomi K. ; Hadley, Mac E. ; Hruby, Victor J ; Dickinson, Chris ; Gantz, Ira. / Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. In: Journal of Medicinal Chemistry. 1997 ; Vol. 40, No. 14. pp. 2133-2139.
@article{d0b7d8c2a7254bd3a2adcdfc906f99be,
title = "Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R",
abstract = "[Nle4,DPhe7]-α-MSH (NDP-MSH), a highly potent analogne of α- melanocyte-stimulating hormone (α-MSH), possesses nanomolar efficacies at all the melanocortin receptor subtypes except the MC2R. Evaluation of the melanocortin 'message' sequence of [Nle4,DPhe7]-α-MSH was performed on the human melanocortin receptor subtypes designated hMC1, hMC3R, hMC4R, and hMC5R. Tetrapeptides and tripeptides were stereochemically modified to explore topochemical preferences at these receptors and to identify lead peptides possessing agonist activity and subtype selectivity. Four peptides were discovered to only bind to the hMC1 and hMC4 receptor subtypes. The tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 (1) possessed 0.6μM binding affinity at the hMC1R, 1.2μM binding affinity at the hMC4R, and agonist activity at both receptors. The tripeptides Ac-DPhe-Arg-Trp-NH2 (6) and Ac-DPhe-Arg- DTrp-NH2 (7) possessed 2.0 and 9.1 μM binding affinities, respectively, only at the hMC4R, and both compounds effected agonist activity. The tetrapeptide Ac-His-Phe-Arg-DTrp-NH2 (4) possessed 6.3μM affinity and full agonist activity at the hMC1R, while only binding 7{\%} at the hMC3R, 36{\%} at the hMC4R, and 11{\%} at the hMC5R at a maximal concentration of 10 μM. These data demonstrate that the His-Phe-Arg-Trp message sequence of the melanocortin peptides does not bind and stimulate each melanocortin receptor in a similar fashion, as previously hypothesized. Additionally, this study identified the simplest structural agonists for the hMC1R and hMC4R receptors reported to date.",
author = "Carrie Haskell-Luevano and Siska Hendrata and Cheryl North and Sawyer, {Tomi K.} and Hadley, {Mac E.} and Hruby, {Victor J} and Chris Dickinson and Ira Gantz",
year = "1997",
month = "7",
day = "4",
doi = "10.1021/jm960840h",
language = "English (US)",
volume = "40",
pages = "2133--2139",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "14",

}

TY - JOUR

T1 - Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R

AU - Haskell-Luevano, Carrie

AU - Hendrata, Siska

AU - North, Cheryl

AU - Sawyer, Tomi K.

AU - Hadley, Mac E.

AU - Hruby, Victor J

AU - Dickinson, Chris

AU - Gantz, Ira

PY - 1997/7/4

Y1 - 1997/7/4

N2 - [Nle4,DPhe7]-α-MSH (NDP-MSH), a highly potent analogne of α- melanocyte-stimulating hormone (α-MSH), possesses nanomolar efficacies at all the melanocortin receptor subtypes except the MC2R. Evaluation of the melanocortin 'message' sequence of [Nle4,DPhe7]-α-MSH was performed on the human melanocortin receptor subtypes designated hMC1, hMC3R, hMC4R, and hMC5R. Tetrapeptides and tripeptides were stereochemically modified to explore topochemical preferences at these receptors and to identify lead peptides possessing agonist activity and subtype selectivity. Four peptides were discovered to only bind to the hMC1 and hMC4 receptor subtypes. The tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 (1) possessed 0.6μM binding affinity at the hMC1R, 1.2μM binding affinity at the hMC4R, and agonist activity at both receptors. The tripeptides Ac-DPhe-Arg-Trp-NH2 (6) and Ac-DPhe-Arg- DTrp-NH2 (7) possessed 2.0 and 9.1 μM binding affinities, respectively, only at the hMC4R, and both compounds effected agonist activity. The tetrapeptide Ac-His-Phe-Arg-DTrp-NH2 (4) possessed 6.3μM affinity and full agonist activity at the hMC1R, while only binding 7% at the hMC3R, 36% at the hMC4R, and 11% at the hMC5R at a maximal concentration of 10 μM. These data demonstrate that the His-Phe-Arg-Trp message sequence of the melanocortin peptides does not bind and stimulate each melanocortin receptor in a similar fashion, as previously hypothesized. Additionally, this study identified the simplest structural agonists for the hMC1R and hMC4R receptors reported to date.

AB - [Nle4,DPhe7]-α-MSH (NDP-MSH), a highly potent analogne of α- melanocyte-stimulating hormone (α-MSH), possesses nanomolar efficacies at all the melanocortin receptor subtypes except the MC2R. Evaluation of the melanocortin 'message' sequence of [Nle4,DPhe7]-α-MSH was performed on the human melanocortin receptor subtypes designated hMC1, hMC3R, hMC4R, and hMC5R. Tetrapeptides and tripeptides were stereochemically modified to explore topochemical preferences at these receptors and to identify lead peptides possessing agonist activity and subtype selectivity. Four peptides were discovered to only bind to the hMC1 and hMC4 receptor subtypes. The tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 (1) possessed 0.6μM binding affinity at the hMC1R, 1.2μM binding affinity at the hMC4R, and agonist activity at both receptors. The tripeptides Ac-DPhe-Arg-Trp-NH2 (6) and Ac-DPhe-Arg- DTrp-NH2 (7) possessed 2.0 and 9.1 μM binding affinities, respectively, only at the hMC4R, and both compounds effected agonist activity. The tetrapeptide Ac-His-Phe-Arg-DTrp-NH2 (4) possessed 6.3μM affinity and full agonist activity at the hMC1R, while only binding 7% at the hMC3R, 36% at the hMC4R, and 11% at the hMC5R at a maximal concentration of 10 μM. These data demonstrate that the His-Phe-Arg-Trp message sequence of the melanocortin peptides does not bind and stimulate each melanocortin receptor in a similar fashion, as previously hypothesized. Additionally, this study identified the simplest structural agonists for the hMC1R and hMC4R receptors reported to date.

UR - http://www.scopus.com/inward/record.url?scp=0030787858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030787858&partnerID=8YFLogxK

U2 - 10.1021/jm960840h

DO - 10.1021/jm960840h

M3 - Article

C2 - 9216831

AN - SCOPUS:0030787858

VL - 40

SP - 2133

EP - 2139

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 14

ER -